Filing Flows › Health Care › BioNexus Gene Lab (BGLC)
BioNexus Gene Lab (BGLC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · BioNexus Gene Lab (BGLC) Q2 2026 earnings results →
Q2 2026 Revenue down 97% year over year to $76K · 376¢ of every $1 of revenue lost · operating margin -370.8%
BioNexus Gene Lab made $76K in Q2 2026 (-97% Y/Y). Operating margin -370.8%, net loss $286K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $76K in Q2 2026, down 97% year over year and up 233% from the previous quarter.
Gross margin was 17.0%, up 0.8 points from Q2 2025. Operating costs exceeded revenue by $282K, an operating margin of -370.8%. Operating expenses fell 70% while revenue fell 97%. The quarter ended with a net loss of $286K, narrower than the previous quarter's $544K loss.
Operating cash flow was −$422K. Non-cash charges added back $28K of depreciation. Working capital and other items used $164K. Capital expenditures of $0K exceeded it, leaving free cash flow of −$423K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $76K | -97% | -370.8% | −$286K | −$422K |
| Q1 2026 | 10-Q | May 15, 2026 | $23K | -99% | n/m | −$544K | −$148K |
| Q4 2025 | 10-K | Apr 14, 2026 | $484K | -81% | -213.5% | −$1.0M | $961K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $2.5M | -3% | -27.6% | −$709K | −$1.2M |
| Q2 2025 | 10-Q | Aug 18, 2025 | $2.3M | +14% | -27.0% | −$616K | −$738K |
| Q1 2025 | 10-Q | May 15, 2025 | $2.1M | -10% | -28.9% | −$623K | −$824K |
| Q4 2024 | 10-K | Apr 15, 2025 | $2.5M | +11% | -16.5% | $348K | −$70K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About BioNexus Gene Lab
BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (“Chemrex”) and MRNA Scientific Sdn. Bhd. (“MRNA Scientific”). Chemrex is engaged in the distribution of chemical raw materials, primarily for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. In November 2025, the Company entered into a Share Subscription and Shareholders’ Agreement with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and related parties, and also entered into an exclusive Southeast Asia intellectual property license arrangement relating to the VitaGuard™ minimal residual disease platform.
In its own words, from its 10-K, filed Apr 14, 2026.
BioNexus Gene Lab against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -97% against the peers' median +10%. Operating margin: -370.8% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BGLC BioNexus Gene Lab | Q2 2026 | $76K | -97% | -370.8% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
Source: BioNexus Gene Lab 10-Q on SEC EDGAR · CIK 1737523 · Services-Medical Laboratories
More on BGLC
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results